Sanofi and Regeneron hosted a conference call for the financial community on sarilumab during the American College of Rheumatology Annual (ACR) Meeting in San Francisco.
Sarilumab is a fully-human monoclonal antibody directed against the IL-6 receptor (IL-6R). This investigational compound is currently in clinical development for Rheumatoid Arthritis. Sarilumab achieved primary efficacy endpoints across all completed pivotal Phase 3 studies, including for TARGET and ASCERTAIN. Data from these two studies were presented as oral presentations at ACR on November 8th.
Related press releases
- November 8, 2015: Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
- May 21, 2015: Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis